panitumumab,bevacizumab
takeda,roche,amgen
['cairo-5', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
cairo-5 adding important data for treatment for mcrc with liver metastases initially unresectable. no pfs differences. better orr with pan vs. beva, still no differences on ressectability. would like to wait to see mature os data. #esmo22 
Oncologista.